CDK14

Summary

CDK14 (cyclin dependent kinase 14, HGNC:8883) is a protein-coding gene on chromosome 7q21.13, encoding Cyclin-dependent kinase 14 (O94921). Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin.

Enables cyclin binding activity and cyclin-dependent protein serine/threonine kinase activity. Involved in G2/M transition of mitotic cell cycle and regulation of canonical Wnt signaling pathway. Located in cytosol; nucleoplasm; and plasma membrane. Part of cytoplasmic cyclin-dependent protein kinase holoenzyme complex.

Source: NCBI Gene 5218 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 84 total
• Phenotypes (HPO): 1
• Druggable target: yes — 17 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001287135

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8883
Approved symbol	CDK14
Name	cyclin dependent kinase 14
Location	7q21.13
Locus type	gene with protein product
Status	Approved
Aliases	PFTAIRE1
Ensembl gene	ENSG00000058091
Ensembl biotype	protein_coding
OMIM	610679
Entrez	5218

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 22 protein_coding, 5 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000265741, ENST00000380050, ENST00000406263, ENST00000430760, ENST00000431029, ENST00000436577, ENST00000446224, ENST00000446790, ENST00000449528, ENST00000456689, ENST00000460493, ENST00000478540, ENST00000484035, ENST00000487145, ENST00000496279, ENST00000859638, ENST00000859639, ENST00000859640, ENST00000859641, ENST00000859642, ENST00000859643, ENST00000915548, ENST00000915549, ENST00000915550, ENST00000915551, ENST00000962109, ENST00000962110, ENST00000962111

RefSeq mRNA: 4 — MANE Select: NM_001287135 NM_001287135, NM_001287136, NM_001287137, NM_012395

CCDS: CCDS5619, CCDS75626, CCDS75627, CCDS75628

Canonical transcript exons

ENST00000380050 — 15 exons

Exon	Start	End
ENSE00001268368	90596321	90596718
ENSE00001615847	90955697	90955817
ENSE00001616277	90984148	90984241
ENSE00001632463	91118065	91118208
ENSE00001639680	91079432	91079480
ENSE00001782824	91112542	91112681
ENSE00001806251	91045897	91045960
ENSE00001918185	91207165	91210590
ENSE00003466371	90747681	90747775
ENSE00003485469	90917601	90917724
ENSE00003537906	90899291	90899353
ENSE00003539445	90726567	90726812
ENSE00003562044	90604218	90604249
ENSE00003624791	90863175	90863269
ENSE00003662659	90790573	90790652

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 98.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.6290 / max 732.0343, expressed in 1592 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79464	5.1111	1392
79460	4.6082	1346
79476	2.8884	193
79466	1.5320	357
79463	1.2738	765
79475	0.9823	150
204514	0.5702	347
79473	0.3507	105
79472	0.3363	97
79477	0.2607	42

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
postcentral gyrus	UBERON:0002581	98.24	gold quality
parietal lobe	UBERON:0001872	98.05	gold quality
CA1 field of hippocampus	UBERON:0003881	98.04	gold quality
substantia nigra pars compacta	UBERON:0001965	97.82	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.70	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.70	gold quality
entorhinal cortex	UBERON:0002728	97.51	gold quality
Brodmann (1909) area 10	UBERON:0013541	97.36	gold quality
superior frontal gyrus	UBERON:0002661	97.01	gold quality
Brodmann (1909) area 46	UBERON:0006483	96.83	gold quality
tendon of biceps brachii	UBERON:0008188	96.47	gold quality
orbitofrontal cortex	UBERON:0004167	96.45	gold quality
frontal pole	UBERON:0002795	96.28	gold quality
endothelial cell	CL:0000115	94.71	gold quality
occipital lobe	UBERON:0002021	93.22	gold quality
prefrontal cortex	UBERON:0000451	93.18	gold quality
primary visual cortex	UBERON:0002436	93.16	gold quality
frontal lobe	UBERON:0016525	93.01	gold quality
frontal cortex	UBERON:0001870	93.00	gold quality
pons	UBERON:0000988	92.86	gold quality
cerebral cortex	UBERON:0000956	92.57	gold quality
superior vestibular nucleus	UBERON:0007227	92.55	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.49	gold quality
neocortex	UBERON:0001950	92.45	gold quality
periodontal ligament	UBERON:0008266	92.45	gold quality
tendon	UBERON:0000043	92.36	gold quality
calcaneal tendon	UBERON:0003701	92.34	gold quality
paraflocculus	UBERON:0005351	92.06	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.78	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.63	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	51.47
E-ANND-3	yes	11.18
E-HCAD-25	yes	7.39
E-GEOD-137537	yes	5.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

196 targeting CDK14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3658	99.96	73.87	4379

Literature-anchored findings (GeneRIF, showing 39)

• Ser119 is crucial for the interaction between hPFTAIRE1 and the 14-3-3 proteins. Binding with the 14-3-3 proteins does not contribute to the subcellular localization of the hPFTAIRE1, although the binding may be involved in its signaling regulation. (PMID:16775625)
• PFTK1 acts as a cyclin-dependent kinase that regulates cell cycle progression and cell proliferation (PMID:17517622)
• Novel biological cascade that involved the phosphorylation activation of CaD by PFTK1 kinase in promoting formation of actin stress fibers. (PMID:21184254)
• Taken together, our data propose a novel, oncogene-tumor suppressor interplay, where oncogenic PFTK1 confers HCC cell motility through inactivating the actin-binding motile suppressing function of TAGLN2 via phosphorylation. (PMID:21577206)
• in patients with oesophageal squamous cell carcinoma 5-year overall survival rate was poorer in patients positive for PFTK1 than those with negative expression; uni- and multivariate analyses identified PFTK1 as an independent marker of prognosis (PMID:22333595)
• binding of CCNY to 14-3-3 significantly enhanced the association between CCNY and CDK14 (PMID:24618387)
• Human cyclin Y (CCNY) is a phosphoprotein in vivo and phosphorylation of CCNY by CDK14 triggers its ubiquitination and degradation. (PMID:24794231)
• findings indicate that brain PP-1I associates with and is regulated by the associated protein kinases C-TAK1 and PFTK1 (PMID:25028520)
• Cigarette smoke down regulates CDK14 levels and impairs Wnt signaling. (PMID:25680692)
• Up-regulated PFTK1 might promote breast cancer progression. (PMID:26033031)
• Knockdown of PFTK1 increases E-cadherin expression, decreases vimentin expression and inhibits migration of glioma cells. (PMID:26234562)
• PFTK1 overexpression promoted proliferation, migration and invasion of gastric cancer cells, while PFTK1 knockdown led to the opposite results. (PMID:26488471)
• The expression level of PFTK1 was correlated with tumor grade, FIGO stage, lymph node metastasis of EOC patients as well as poor prognosis. (PMID:26772918)
• Knockdown of PFTK1 inhibited the proliferation and invasion of pancreatic cancer cells as well as the EMT progress by suppressing the PI3K/Akt signaling pathway. (PMID:26823712)
• these results suggest that knockdown of PFTK1 inhibited the proliferation and invasion of colon cancer cells as well as the EMT progress by suppressing the Sonic hedgehog signaling pathway. (PMID:27458094)
• we report that PFTK1 downregulation might inhibit the proliferation and invasion of NSCLC cells by suppressing the Wnt/beta-catenin signaling pathway. (PMID:27458099)
• findings revealed an unrecognized role of Caprin-2 in facilitating LRP5/6 constitutive phosphorylation at G2/M through forming a quaternary complex with CDK14, Cyclin Y, and LRP5/6. (PMID:27821587)
• miR-455 inhibits breast cancer cell proliferation through targeting CDK14 (PMID:28300591)
• PFTK1 expression is significantly higher in CRC tissues compared with matched adjacent noncancerous colorectal tissues. The associations between PFTK1 expression and clinicopathological characters, and PFTK1 expression and the OS rate following resection suggested that PFTK1 may represent a novel biomarker of poor prognosis in CRC (PMID:28498444)
• CDK14 expression was closely associated with poor prognosis and overall survival of Osteosarcoma patients. miR-216a inhibits CDK14 expression by binding to the 3’-untranslated region of CDK14. (PMID:29022909)
• Results show that CDK14 and DYRK2 expression were inversely correlated in human breast cancer tissues and identified CDK14 as a target of DYRK2. (PMID:29193658)
• CDK14 mediated miR-1202 to exert its anti-tumor effects. (PMID:29217161)
• Data suggest the risk-associated single nucleotide polymorphism (SNP) rs10272859 of cyclin dependent kinase 14 (CDK14) gene at 7q21.13 conferring both susceptibility and prognosis to HBV-related hepatocellular carcinoma (HCC). (PMID:29246937)
• MiR-431 expression was reduced both in pancreatic cancer tissues and cell lines. Cell proliferative ability was effectively lessened after up-regulating miR-431. Elevated miR-431 significantly induced cell apoptosis and modulated cell cycle arrest. Meanwhile, CDK14 was a direct target gene of miR-431, and over-expression of miR-431 decreased the level of CDK14. (PMID:30058687)
• OIP5-AS1 acts as a miR-223 ‘sponge’ to trigger CDK14 expression to promote osteosarcoma tumorigenesis. (PMID:30119217)
• knockdown of E2F5 and PFTK1 mimicked the tumor-suppressive effects of miR-1-3p overexpression on PCa progression. Conversely, concomitant knockdown of miR-1-3p and E2F5 and PFTK1 substantially reversed the inhibitory effects of either E2F5 or PFTK1 silencing alone. (PMID:30185212)
• LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer. (PMID:30474270)
• our findings indicated that NEAT1/miR-107/CDK14 axis participated in glioma development. NEAT1 could act as a significant prognostic biomarker in glioma progression. (PMID:30480816)
• CDK14 overexpression reversed the suppressive effects of miR-542-3p in ovarian cancer cells. (PMID:30557834)
• we demonstrated that MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14. We provided a novel experimental basis for PDAC treatment from the perspective of lncRNA-miRNA-mRNA network. (PMID:30915884)
• Upregulation of miR-1825 inhibits the progression of glioblastoma by suppressing CDK14 though Wnt/beta-catenin signaling pathway. (PMID:32605563)
• CircCDK14 protects against Osteoarthritis by sponging miR-125a-5p and promoting the expression of Smad2. (PMID:32802182)
• MiR-205 Inhibits Sporadic Vestibular Schwannoma Cell Proliferation by Targeting Cyclin-Dependent Kinase 14. (PMID:33217595)
• LncRNA NORAD accelerates the progression of non-small cell lung cancer via targeting miRNA-455/CDK14 axis. (PMID:33764714)
• Depletion of circRNA circ_CDK14 inhibits osteosarcoma progression by regulating the miR-520a-3p/GAB1 axis. (PMID:34348465)
• CircCDK14 Promotes Tumor Progression and Resists Ferroptosis in Glioma by Regulating PDGFRA. (PMID:35002529)
• P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC. (PMID:37599359)
• Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy. (PMID:38575601)
• N6-methyladenosine-modified circCDK14 promotes ossification of the ligamentum flavum via epigenetic modulation by targeting AFF4. (PMID:39414635)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdk14	ENSDARG00000074665
mus_musculus	Cdk14	ENSMUSG00000028926
rattus_norvegicus	Cdk14	ENSRNOG00000007151

Paralogs (26): CDKL3 (ENSG00000006837), CDKL5 (ENSG00000008086), CDK11A (ENSG00000008128), CDK17 (ENSG00000059758), CDK13 (ENSG00000065883), CDKL1 (ENSG00000100490), CDK16 (ENSG00000102225), CDK6 (ENSG00000105810), PRP4K (ENSG00000112739), CDK18 (ENSG00000117266), CDK2 (ENSG00000123374), CDK8 (ENSG00000132964), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446), CDK9 (ENSG00000136807), CDK15 (ENSG00000138395), CDKL2 (ENSG00000138769), CDK19 (ENSG00000155111), CDK20 (ENSG00000156345), CDK5 (ENSG00000164885), CDK12 (ENSG00000167258), CDK1 (ENSG00000170312), CDK10 (ENSG00000185324), CDKL4 (ENSG00000205111), CDK11B (ENSG00000248333), CDK3 (ENSG00000250506)

Protein

Protein identifiers

Cyclin-dependent kinase 14 — O94921 (reviewed: O94921)

Alternative names: Cell division protein kinase 14, Serine/threonine-protein kinase PFTAIRE-1

All UniProt accessions (5): O94921, C9IYJ9, C9JWL6, E7EUK8, F8WF96

UniProt curated annotations — full annotation on UniProt →

Function. Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin. Acts as a cell-cycle regulator of Wnt signaling pathway during G2/M phase by mediating the phosphorylation of LRP6 at ‘Ser-1490’, leading to the activation of the Wnt signaling pathway. Acts as a regulator of cell cycle progression and cell proliferation via its interaction with CCDN3. Phosphorylates RB1 in vitro, however the relevance of such result remains to be confirmed in vivo. May also play a role in meiosis, neuron differentiation and may indirectly act as a negative regulator of insulin-responsive glucose transport.

Subunit / interactions. Found in a complex with LRP6, CCNY and CAPRIN2 during G2/M stage; CAPRIN2 functions as a scaffold for the complex by binding to CCNY via its N terminus and to CDK14 via its C terminus. Interacts with CCNY; CCNY mediates its recruitment to the plasma membrane and promotes phosphorylation of LRP6. Interacts with CCDN3 and CDKN1A. Interacts with SEPT8. Interacts with 14-3-3 proteina YWHAB, YWHAE, YWHAH and YWHAQ.

Subcellular location. Cell membrane. Cytoplasm. Nucleus.

Tissue specificity. Highly expressed in brain, pancreas, kidney, heart, testis and ovary. Also detected at lower levels in other tissues except in spleen and thymus where expression is barely detected.

Activity regulation. Serine/threonine-protein kinase activity is promoted by associated cyclins CCDN3 and CCNY and repressed by CDKN1A.

Similarity. Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
O94921-1	1	yes
O94921-2	2
O94921-3	3

RefSeq proteins (4): NP_001274064, NP_001274065, NP_001274066, NP_036527 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR050108	CDK	Family

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (19 total): modified residue 4, splice variant 2, sequence variant 2, sequence conflict 2, region of interest 2, binding site 2, chain 1, domain 1, mutagenesis site 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94921-F1	71.10	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 256 (proton acceptor)

Ligand- & substrate-binding residues (2): 141–149; 164

Post-translational modifications (4): 95, 134, 24, 78

Mutagenesis-validated functional residues (1):

Position	Phenotype
164	abolishes protein kinase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 332 (showing top): DAVIES_MULTIPLE_MYELOMA_VS_MGUS_DN, AP1_01, FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN, GAANYNYGACNY_UNKNOWN, AREB6_03, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GOBP_CELL_CYCLE_PHASE_TRANSITION, GEORGES_CELL_CYCLE_MIR192_TARGETS, TGACCTY_ERR1_Q2, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, EVI1_05, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, SASSON_RESPONSE_TO_FORSKOLIN_DN, GOBP_REGULATION_OF_CELL_CYCLE, CAATGCA_MIR33

GO Biological Process (6): G2/M transition of mitotic cell cycle (GO:0000086), Wnt signaling pathway (GO:0016055), cell division (GO:0051301), regulation of canonical Wnt signaling pathway (GO:0060828), regulation of cell cycle phase transition (GO:1901987), protein phosphorylation (GO:0006468)

GO Molecular Function (11): cyclin-dependent protein serine/threonine kinase activity (GO:0004693), ATP binding (GO:0005524), cyclin binding (GO:0030332), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), heme binding (GO:0020037)

GO Cellular Component (8): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), cytoplasmic cyclin-dependent protein kinase holoenzyme complex (GO:0000308), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
protein kinase activity	2
cytoplasm	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G2/M phase transition	1
cell surface receptor signaling pathway	1
cellular process	1
regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of cell cycle process	1
cell cycle phase transition	1
phosphorylation	1
protein modification process	1
protein serine/threonine kinase activity	1
cyclin-dependent protein kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
tetrapyrrole binding	1
serine/threonine protein kinase complex	1
cyclin-dependent protein kinase holoenzyme complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

2983 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDK14	CCNY	Q8ND76	992
CDK14	CCND3	P30281	756
CDK14	AKT3	Q9Y243	610
CDK14	CCNL2	Q96S94	602
CDK14	CCNYL1	Q8N7R7	573
CDK14	YWHAH	Q04917	458
CDK14	YWHAB	P31946	453
CDK14	LRP6	O75581	439
CDK14	ZNF148	Q9UQR1	439
CDK14	SFN	P31947	422
CDK14	YWHAQ	P27348	421
CDK14	CILK1	Q9UPZ9	420
CDK14	YWHAE	P29360	415
CDK14	GPATCH3	Q96I76	408
CDK14	RSPRY1	Q96DX4	399

IntAct

62 interactions, top by confidence:

A	B	Type	Score
CDK5	FIBP	psi-mi:“MI:0914”(association)	0.840
YWHAB	PIK3C2A	psi-mi:“MI:0914”(association)	0.800
YWHAH	CDK14	psi-mi:“MI:0915”(physical association)	0.780
CDK14	YWHAH	psi-mi:“MI:0915”(physical association)	0.780
CDKN1A	CDK14	psi-mi:“MI:0915”(physical association)	0.770
CDK14	CDKN1A	psi-mi:“MI:0915”(physical association)	0.770
CDKN1A	CDK14	psi-mi:“MI:0914”(association)	0.770
CDK14	CDKN1A	psi-mi:“MI:0914”(association)	0.770
CDK14	YWHAB	psi-mi:“MI:0915”(physical association)	0.750
YWHAB	CDK14	psi-mi:“MI:0915”(physical association)	0.750
YWHAQ	CDK14	psi-mi:“MI:0915”(physical association)	0.720
CDK14	YWHAQ	psi-mi:“MI:0915”(physical association)	0.720
YWHAG	BLTP3B	psi-mi:“MI:0914”(association)	0.640
ELL3	CCNT1	psi-mi:“MI:0914”(association)	0.640
CDK14	YWHAE	psi-mi:“MI:0915”(physical association)	0.630
YWHAE	CDK14	psi-mi:“MI:0915”(physical association)	0.630
CDK14	CCND3	psi-mi:“MI:0915”(physical association)	0.620
CCND3	CDK14	psi-mi:“MI:0915”(physical association)	0.620
CDK14	CCND3	psi-mi:“MI:0914”(association)	0.620

BioGRID (90): CDK14 (Affinity Capture-MS), HSP90AA5P (Affinity Capture-MS), CDK17 (Affinity Capture-MS), ICK (Affinity Capture-MS), CDKN1A (Affinity Capture-MS), CDK14 (Affinity Capture-MS), CDK14 (Affinity Capture-MS), ICK (Affinity Capture-MS), FGR (Affinity Capture-MS), CDKN1A (Affinity Capture-MS), CDK17 (Affinity Capture-MS), CDK14 (Affinity Capture-MS), CDK14 (Affinity Capture-MS), HSP90AA5P (Affinity Capture-MS), CDK14 (Affinity Capture-MS)

ESM2 similar proteins: A0A8I3S724, A4IGM9, A4IIW7, A5GFW1, B0VXL7, B6A7Q3, C0RW22, D7UQM5, F4I4F2, O08605, O14965, O35495, O55099, O59790, O70126, O80673, O94921, P18266, P27466, P49841, P59241, P97477, Q00771, Q0VD22, Q13555, Q16566, Q2TA06, Q501Q9, Q58D94, Q5XIT0, Q66JF3, Q6BVA0, Q6C3J2, Q6CWQ4, Q6DE08, Q6DGS3, Q6GPL3, Q6Z8C8, Q755C4, Q7YRC6

Diamond homologs: A4IIW7, A8XA58, B0VXE8, B0VXL7, B6A7Q3, C0RW22, G5ECH7, O35495, O35831, O35832, O55076, O61847, O74456, O94921, O96821, P00546, P04551, P06493, P11440, P13863, P17157, P23111, P23437, P23572, P23573, P24033, P24100, P24923, P24941, P25859, P29618, P29619, P34112, P34117, P35567, P38973, P39951, P43063, P43450, P48609

SIGNOR signaling

8 interactions.

A	Effect	B	Mechanism
CCNY	up-regulates	CDK14	binding
CDK14	up-regulates	LRP6	phosphorylation
CDK14	“down-regulates quantity by destabilization”	CCNY	phosphorylation
CDK14	“down-regulates activity”	TAGLN2	phosphorylation
CDK14	“form complex”	CyclinY/CDK14	binding
CDK14	“up-regulates activity”	LRP6

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 32 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	169.2×	8e-11
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	149.3×	1e-10
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	149.3×	1e-10
Activation of BH3-only proteins	6	110.3×	5e-10
FOXO-mediated transcription	6	74.6×	5e-09
RHO GTPases activate PKNs	6	70.5×	7e-09
Intrinsic Pathway for Apoptosis	6	65.1×	1e-08
SARS-CoV-1-host interactions	6	39.0×	2e-07

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	61.1×	6e-06
intracellular protein localization	6	20.9×	6e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

84 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	58
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

3576 predictions. Top by Δscore:

Variant	Effect	Δscore
7:90596701:A:T	donor_gain	1.0000
7:90596714:CATTG:C	donor_gain	1.0000
7:90596715:ATTG:A	donor_gain	1.0000
7:90596716:TTG:T	donor_gain	1.0000
7:90596717:TG:T	donor_gain	1.0000
7:90596717:TGG:T	donor_loss	1.0000
7:90596718:GG:G	donor_gain	1.0000
7:90596718:GGT:G	donor_loss	1.0000
7:90596719:G:GG	donor_gain	1.0000
7:90596719:GTG:G	donor_loss	1.0000
7:90596720:T:A	donor_loss	1.0000
7:90604215:T:G	acceptor_gain	1.0000
7:90604216:A:AG	acceptor_gain	1.0000
7:90604217:G:GA	acceptor_gain	1.0000
7:90720946:T:G	donor_gain	1.0000
7:90726562:CTCA:C	acceptor_loss	1.0000
7:90726562:CTCAG:C	acceptor_gain	1.0000
7:90726563:TCA:T	acceptor_loss	1.0000
7:90726563:TCAGA:T	acceptor_gain	1.0000
7:90726564:CA:C	acceptor_loss	1.0000
7:90726564:CAG:C	acceptor_gain	1.0000
7:90726565:A:AG	acceptor_gain	1.0000
7:90726565:A:C	acceptor_gain	1.0000
7:90726566:G:GG	acceptor_gain	1.0000
7:90726566:G:T	acceptor_gain	1.0000
7:90726566:GA:G	acceptor_gain	1.0000
7:90726566:GAT:G	acceptor_gain	1.0000
7:90726566:GATA:G	acceptor_gain	1.0000
7:90726566:GATAT:G	acceptor_gain	1.0000
7:90726808:GCTCG:G	donor_gain	1.0000

AlphaMissense

3090 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:90747700:G:A	G130E	1.000
7:90747714:T:C	Y135H	1.000
7:90747714:T:G	Y135D	1.000
7:90747735:G:A	G142R	1.000
7:90747735:G:C	G142R	1.000
7:90747735:G:T	G142W	1.000
7:90747736:G:A	G142E	1.000
7:90747736:G:T	G142V	1.000
7:90747741:G:A	G144R	1.000
7:90747741:G:C	G144R	1.000
7:90747742:G:A	G144E	1.000
7:90747742:G:C	G144A	1.000
7:90747742:G:T	G144V	1.000
7:90747747:T:C	Y146H	1.000
7:90747750:G:C	A147P	1.000
7:90747751:C:A	A147D	1.000
7:90747751:C:T	A147V	1.000
7:90747756:G:C	V149L	1.000
7:90747756:G:T	V149L	1.000
7:90747757:T:A	V149E	1.000
7:90747757:T:C	V149A	1.000
7:90747765:G:A	G152R	1.000
7:90747765:G:C	G152R	1.000
7:90747765:G:T	G152W	1.000
7:90747766:G:A	G152E	1.000
7:90790593:C:A	A162D	1.000
7:90790596:T:C	L163P	1.000
7:90790598:A:C	K164Q	1.000
7:90790598:A:G	K164E	1.000
7:90790599:A:C	K164T	1.000

dbSNP variants (sampled 300 via entrez): RS1000000124 (7:90808588 A>C,G), RS1000002381 (7:91010553 T>C), RS1000005396 (7:91190235 T>C), RS1000009321 (7:90896895 T>C), RS1000013991 (7:91097103 G>A), RS1000016533 (7:90969360 C>A,T), RS1000016967 (7:91033736 A>G), RS1000026835 (7:90888081 A>G), RS1000028586 (7:90686939 C>G), RS1000029264 (7:90678440 G>C), RS1000030930 (7:90601714 G>T), RS1000032657 (7:90765296 A>G), RS1000044041 (7:90603752 A>C), RS1000050859 (7:91141564 G>T), RS1000053545 (7:90915511 A>C,G)

Disease associations

OMIM: gene MIM:610679 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002707_8	Serum thyroid-stimulating hormone levels	5.000000e-06
GCST004361_1	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer	1.000000e-06
GCST005570_1	Hepatitis B virus-related hepatocellular carcinoma	9.000000e-10
GCST006491_18	Circulating fibroblast growth factor 23 levels	2.000000e-06
GCST006626_4	Pulse pressure	1.000000e-13
GCST007269_273	Pulse pressure	3.000000e-09
GCST010396_95	Gut microbiota (bacterial taxa, hurdle binary method)	1.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007970	estrone measurement
EFO:0007972	androstenedione measurement
EFO:0005763	pulse pressure measurement
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL3559691 (PROTEIN FAMILY), CHEMBL4296115 (PROTEIN COMPLEX), CHEMBL6162 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

17 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 229,940 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1336	SORAFENIB	4	86,060
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL300138	ENZASTAURIN	3	3,209
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL603469	LESTAURTINIB	3
CHEMBL1276127	INDIRUBIN	2	181
CHEMBL445813	AT-7519	2	2,614
CHEMBL5199065	ISTISOCICLIB	2	21
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL1721885	SU-014813	2	363
CHEMBL384304	RG-547	2	93
CHEMBL1908397	KW-2449	1	622
CHEMBL296468	BMS-387032	1	2,075
CHEMBL574738	AST-487	1	451

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — TAIRE subfamily

Binding affinities (BindingDB)

7 measured of 7 human assays (7 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide	KD	370 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
BMS-387072	KD	1800 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S)-3-hydroxy-1-methyl-4-piperidinyl]-1-benzopyran-4-one	KD	5300 nM

ChEMBL bioactivities

114 potent at pChembl≥5 of 115 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.40	IC50	0.4	nM	CHEMBL4563703
9.10	IC50	0.8	nM	CHEMBL4535078
8.80	IC50	1.6	nM	CHEMBL4446451
8.74	IC50	1.8	nM	CHEMBL4522598
8.59	IC50	2.6	nM	CHEMBL4515515
8.52	IC50	3	nM	CHEMBL4542127
8.52	IC50	3	nM	CHEMBL4530961
8.47	IC50	3.4	nM	CHEMBL4527767
8.19	IC50	6.4	nM	CHEMBL4579572
8.00	IC50	10	nM	CHEMBL4519165
7.96	IC50	11	nM	CHEMBL4456492
7.96	Kd	11	nM	RG-547
7.85	IC50	14	nM	CHEMBL4459422
7.85	IC50	14	nM	CHEMBL4563705
7.80	Kd	16	nM	AT-7519
7.79	IC50	16.1	nM	CHEMBL6144731
7.77	IC50	17	nM	CHEMBL4555069
7.77	Kd	17	nM	AST-487
7.70	IC50	19.8	nM	AT-7519
7.57	IC50	27	nM	CHEMBL4589122
7.51	Kd	31	nM	FORETINIB
7.47	IC50	34	nM	CHEMBL4473682
7.41	IC50	39	nM	CHEMBL4580787
7.40	IC50	39.6	nM	CHEMBL4434727
7.39	IC50	41	nM	CHEMBL4584359
7.35	IC50	45	nM	CHEMBL4554744
7.35	IC50	45	nM	CHEMBL4576258
7.32	IC50	48	nM	CHEMBL4544087
7.31	IC50	49	nM	CHEMBL4474689
7.30	IC50	50	nM	CHEMBL4464758
7.30	IC50	50	nM	CHEMBL4522598
7.30	IC50	50	nM	CHEMBL4542127
7.21	IC50	62	nM	CHEMBL4586749
7.20	IC50	62.7	nM	CHEMBL4856177
7.17	IC50	68	nM	CHEMBL4583677
7.14	IC50	72	nM	CHEMBL4466362
7.11	IC50	77	nM	CHEMBL4459085
7.11	IC50	78.4	nM	CHEMBL4848734
7.09	IC50	82	nM	CHEMBL4447871
7.09	IC50	82	nM	CHEMBL4466865
7.08	IC50	83	nM	CHEMBL4556640
7.08	IC50	83.8	nM	STAUROSPORINE
7.06	IC50	88	nM	CHEMBL4580787
7.06	IC50	88	nM	CHEMBL4435761
7.06	IC50	88	nM	CHEMBL4434727
7.00	IC50	101	nM	STAUROSPORINE
6.97	IC50	108	nM	CHEMBL4536978
6.96	Kd	110	nM	ALVOCIDIB
6.93	IC50	117	nM	CHEMBL4561411
6.90	IC50	126	nM	CHEMBL4444448

PubChem BioAssay actives

112 with measured affinity, of 440 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[(2,6-dichloro-3-methoxybenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0004	uM
4-[(2-chloro-6-methoxybenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0008	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[3-(prop-2-enoylamino)phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0010	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0010	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0010	uM
4-[(2-fluoro-6-methoxybenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0016	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0018	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0026	uM
4-benzamido-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0030	uM
4-[(2-chloro-6-methoxybenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0030	uM
4-[(2,6-difluorobenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0034	uM
4-[(2,6-dichloro-3-methoxybenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0064	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[4-(prop-2-enoylamino)phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0100	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-(propanoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0110	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	625070: Binding constant for PFTK1 kinase domain	kd	0.0110	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0140	uM
N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-4-[[2-(2-methoxyphenyl)acetyl]amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0140	uM
4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide	625070: Binding constant for PFTK1 kinase domain	kd	0.0160	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435689: Binding constant for full-length PFTK1	kd	0.0170	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[4-[[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0170	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0270	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	625070: Binding constant for PFTK1 kinase domain	kd	0.0310	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[3-[[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0340	uM
N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide	1890188: Inhibition of CDK14 (unknown origin) incubated for 6 hrs by NanoBRET assay	ic50	0.0390	uM
N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633948: Inhibition of recombinant NanoLuc-tagged CDK14/cyclin Y expressed in human HCT116 cells at 1 uM incubated for 20 to 24 hrs by by NanoBRET assay	ic50	0.0396	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[(3R)-1-[4-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]sulfonylpyrrolidin-3-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0410	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0450	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0450	uM
N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trimethoxybenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0480	uM
N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0490	uM
4-[(2,6-dimethoxybenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0500	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0620	uM
4-(4-methylpiperazin-1-yl)-N-[4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]quinolin-7-amine	1771107: Inhibition of human CDK14/cyclin-Y using RB protein as substrate incubated for 2 hrs by [gamma-33P]-ATP assay	ic50	0.0627	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[4-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0680	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[3-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0720	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0770	uM
3-acetyl-7-[[4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]amino]-4-morpholin-4-ylchromen-2-one	1771107: Inhibition of human CDK14/cyclin-Y using RB protein as substrate incubated for 2 hrs by [gamma-33P]-ATP assay	ic50	0.0784	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0820	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[3-(propanoylamino)phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0820	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0830	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	2198169: Inhibition of human CDK14/cyclin Y using RB Protein as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by radiometric Hot-SpotSM Kinase assay	ic50	0.0838	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0880	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]methyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1080	uM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one	435689: Binding constant for full-length PFTK1	kd	0.1100	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[(3R)-1-[4-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]pyrrolidin-3-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1170	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-(prop-2-enoylamino)benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1260	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]piperidin-3-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1480	uM
N-[(3R)-1-[[3-[[(E)-but-2-enoyl]amino]phenyl]methyl]pyrrolidin-3-yl]-4-[(2,6-dichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1510	uM
N-[1-[4-[[(E)-but-2-enoyl]amino]phenyl]piperidin-4-yl]-4-[(2,6-dichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1540	uM
N-[3-cyclopropyl-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-5-methyl-18-oxo-9-oxa-17,23,25,26-tetrazatetracyclo[17.5.2.14,8.022,25]heptacosa-1(24),4,6,8(27),19(26),20,22-heptaen-2-yne-6-carboxamide	2014049: Inhibition of CDK14 (unknown origin)	ic50	0.1552	uM

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	5
Valproic Acid	affects expression, decreases expression, decreases methylation	3
Aflatoxin B1	affects expression, decreases expression, decreases methylation	3
Air Pollutants	affects expression, increases abundance, decreases expression	2
Smoke	increases abundance, decreases expression	2
Tretinoin	decreases expression, increases expression	2
Cyclosporine	decreases expression, decreases methylation	2
aristolochic acid I	decreases expression	1
geldanamycin	increases expression	1
methyleugenol	decreases expression	1
bisphenol A	affects methylation	1
trichostatin A	decreases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
ochratoxin A	decreases acetylation, decreases expression	1
benzo(e)pyrene	affects methylation	1
potassium chromate(VI)	decreases expression	1
nickel sulfate	decreases expression	1
coumarin	increases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	increases reaction, affects binding	1
3-nitrobenzanthrone	decreases expression	1
torcetrapib	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1

ChEMBL screening assays

179 unique, capped per target: 179 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1064257	Binding	Inhibition of CDK in human A2780 cells assessed as reduction of RNAP2 phosphorylation at Ser2 site at 5 uM after 6 hrs by Western bloting	Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SI24	HAP1 CDK14 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms